Navigation Links
Lack of a key enzyme dramatically increases resistance to sepsis

According to the new study, the presence of caspase-12, which appears to modulate inflammation and innate immunity in humans, increases the body's "vulnerability to bacterial infection and septic shock" while a deficiency confers strong resistance to sepsis. This new discovery suggests that caspase-12 antagonists could be a potentially useful in the treatment of sepsis and other inflammatory and immune disorders.

The study was published in the April 20 edition of the journal Nature (Volume 440, Number 7087).

Richard Ulevitch, chair of the Scripps Research Immunology Department and an author of the paper, says, "The results of the study make clear that caspase-12 plays a critical role in the elimination of bacterial pathogens, and that a deficiency allows systemic and abdominal infections to be better resolved. It's known that the presence of caspase-12 as a full length protein occurs in a small percentage of people of African descent. As a result, some of these individuals are far more susceptible to severe sepsis and have a significantly increased risk of dying from it."

Sepsis, the body's inflammatory response to severe infection, is one of the leading causes of death in the United States, killing more than 200,000 people each year, according to the Society of Critical Care Medicine. A 2003 study by The Centers for Disease Control and Emory University School of Medicine showed that the incidence of sepsis in the United States has increased almost nine percent a year since 1979.

The new study showed that caspase-12 deficient mice were resistant to peritonitis and septic shock and were able to clear pathogenic bacteria more efficiently than mice with the enzyme. The presence of caspase-12 also reduced production of several pro-inflammatory cytokines, increasing vulnerability to bacterial infection and septic mortality.

"Without the experimental model of peritonitis perfected by John Mathison from Scripps Research, we would not have been able to differentiate between the two mouse phenotypes," Ulevitch said. "Because of his work, we were able to use a surgically implanted stent in the colon that allowed a gradual occurrence of sepsis and easy identification."

A majority of mice with caspace-12 died from sepsis within the first 48 hours after onset, while 60 percent of the caspase-12 deficient mice survived. The deficient mice also showed a significantly lower number of bacterial colony-forming units per milliliter of blood, suggesting that more efficient bacterial clearance occurs in the absence of caspase-12.

Caspase-12 is also an inhibitor of caspase-1, a related enzyme involved in the inflammation process. Caspase-1 deficient mice are two-to-three times more susceptible to lethal Escherichia coli infection than normal mice. Consequently, the study said, sepsis resistance in caspase-12 deficient mice was most likely due to an initial hyper-production of cytokines that fight the infection.

"The resulting beneficial effect of cytokine hyper-production runs contrary to some of the current thinking in sepsis research," Ulevitch said. "The general thinking is that this initial cytokine 'storm' is harmful, and that belief has been the basis of a number of unsuccessful clinical studies. In our study, cells containing caspase-12 appear to weaken the activity of caspase-1 that is normally essential for bacterial clearance and sepsis survival."

In another finding, researchers showed that both mouse models had similar levels of stress-induced apoptosis or programmed cell death. While caspase-12 was previously thought to be a key mediator of endoplasmic reticulum apoptosis, the new study found that the presence or absence of caspase-12 had no effect on apoptotic sensitivity whatsoever.

Others authors of the study include Maya Saleh (currently with McGill University), Melissa K. Wolinski, Steve J. Bensinger, Patrick Fitzgerald, Nathalie Droin, Dougl as R. Green (La Jolla Institute of Allergy and Immunology and St. Jude Children's Research Hospital); Donald W. Nicholson of Merck Research Laboratories, and; John C. Mathison of Scripps Research.


'"/>

Source:Scripps Research Institute


Related biology news :

1. Lack of enzyme turns fat cells into fat burners
2. Scientists find missing enzyme for tuberculosis iron scavenging pathway
3. Researchers report new pro-inflammatory role for anti-inflammatory enzyme
4. Purdue researchers use enzyme to clip DNA wires
5. Scientists take aim at virulent bacteria by decoding machinery of key control enzyme
6. VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells
7. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
8. UCLA researchers identify key enzyme linked to childhood blindness
9. K-State professors discover enzyme responsible for creation of a beetles hard shell
10. Smoking damages key regulatory enzyme in the lung
11. New discovery: If it werent for this enzyme, decomposing pesticide would take millennia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2019)... ... 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived ... clinical trial for stem cell treatment of knee osteoarthritis . The first treatment came ... of VetStem Biopharma. , In July of 2019, PSC received FDA approval ...
(Date:11/12/2019)... , ... November 12, 2019 ... ... a global leader in the design and manufacturer of technical ergonomic seating ... and adjustable footrests compliant with Healthier Hospital Initiative guidelines. Established by Practice ...
(Date:11/12/2019)... ... November 12, 2019 , ... The Arnold and ... universities and research institutions for its Instrumentation Grant for Advanced Light-Sheet Microscopy ... million per site for the acquisition of instrumentation, development and maintenance; support for ...
Breaking Biology News(10 mins):
(Date:10/29/2019)... HOUSTON (PRWEB) , ... October 29, 2019 , ... ... firm, is pleased to announce its Silver sponsorship and cold chain validation workshop ... La Jolla Torrey Pines in San Diego, California. , The Biomanufacturing World ...
(Date:10/22/2019)... ... October 22, 2019 , ... Enplug , a leading ... System into its digital signage platform. The collaboration brings one of the most ... users to leverage their existing digital signage networks to quickly disseminate critical safety ...
(Date:10/10/2019)... ... October 09, 2019 , ... The International Society ... FDA, as a newly-confirmed keynote speaker for the 2019 ISPE Annual Meeting ... , Dr. Abernethy, a hematologist/oncologist and palliative medicine physician, is an internationally recognized ...
(Date:10/8/2019)... ... October 07, 2019 , ... Erchonia Corporation, the ... (“3LT®â€), today announces that the U.S. Food and Drug Administration (FDA) has granted ... the temporary relief of chronic neck and shoulder pain of musculoskeletal origin. , ...
Breaking Biology Technology: